Johnson & Johnson beats profit estimates on pharma strength, raises sales outlook

Johnson & Johnson hiked its full-year operational sales forecast as strong demand for its cancer drugs Darzalex and Imbruvica helped it beat estimates for second-quarter profit on Tuesday.